Aditxt Inc (ADTX) Stock Price, Quote & News

Company Profile

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 870 1200

Website: www.aditxt.com

Address:

2569 Wyandotte Street, Suite 101, Mountain View, United States

ThomasJerryLLC Oct. 4 at 3:55 AM

$ADTX https://m.youtube.com/watch?v=2mkm_mNiJME&list=RD2mkm_mNiJME&start_radio=1&pp=ygUXdGhlcmUncyBubyBlYXN5IHdheSBvdXSgBwHSBwkJ-wkBhyohjO8%3D pardon Amro

0 · Reply

ijusshtmadrorss Oct. 3 at 3:16 PM

$ADTX short short short short.

0 · Reply

simonsteve Oct. 3 at 2:21 PM

$ADTX these idiots be doing split every year they hike the price up to make people buy at the top and they start draining the money gradually and split and repeat 🤬🤬🤬🤬

1 · Reply

VolticRaider2 Oct. 3 at 2:14 PM

$ADTX Let’s all shit on this stock cause we shorted it to .50! And now that it’s stable we are screwed! We gotta get it down!

0 · Reply

flyingcoyote Oct. 3 at 1:44 PM

$ADTX fraudulent company stealing American dollars.

0 · Reply

Ragnarok_74 Oct. 3 at 3:11 AM

$ADTX

0 · Reply

MoonCowBoy Oct. 3 at 1:40 AM

$FAMI $ADTX $NAOV $APDN (

0 · Reply

FrostyDaPoMan Oct. 2 at 11:24 PM

$ADTX It’s all true! Everything you read here from the bears is true! You cannot “trade” this. There is nothing here to “invest” in. If ANY of your money is being “risked” here, it’s already gone. They will split your shares down to the atomic level! They do it every year now like Christmas! A 1:250 split is just ruthless. Should be criminal! Behold! This is the fate that awaits you!

1 · Reply

1Spartantrade1 Oct. 2 at 6:59 PM

Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $FAMI $BHAT $ADTX $NAOV 🔥

0 · Reply

exile0002 Oct. 2 at 5:28 PM

$ADTX as written ... fraudsters doing their job ..... see you sub 0,50 soon. This management f.... on their SH .... to spend money in this trash means to throw it away !!!! This is worst piece of shit in entire market !!!

0 · Reply

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 9, 2025, 9:28 AM EDT - 25 days ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aug 25, 2025, 9:15 AM EDT - 5 weeks ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 21, 2025, 8:56 AM EDT - 6 weeks ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 19, 2025, 9:39 AM EDT - 6 weeks ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 14, 2025, 8:46 AM EDT - 7 weeks ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 11, 2025, 8:30 AM EDT - 7 weeks ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 5, 2025, 8:46 AM EDT - 2 months ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Jul 29, 2025, 9:00 AM EDT - 2 months ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 24, 2025, 8:15 AM EDT - 2 months ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 22, 2025, 8:15 AM EDT - 2 months ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 15, 2025, 9:12 AM EDT - 2 months ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 7, 2025, 8:15 AM EDT - 3 months ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jun 26, 2025, 8:15 AM EDT - 3 months ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 11, 2025, 8:14 AM EDT - 4 months ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 9, 2025, 8:15 AM EDT - 4 months ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 5, 2025, 8:15 AM EDT - 4 months ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

May 19, 2025, 8:00 AM EDT - 4 months ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 2, 2025, 9:00 AM EDT - 5 months ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Apr 17, 2025, 8:15 AM EDT - 6 months ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 16, 2025, 8:15 AM EDT - 6 months ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 14, 2025, 8:15 AM EDT - 6 months ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 11, 2025, 8:15 AM EDT - 6 months ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 6 months ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 2, 2025, 8:15 AM EDT - 6 months ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Mar 28, 2025, 8:15 AM EDT - 6 months ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 24, 2025, 8:30 AM EDT - 6 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:15 AM EDT - 6 months ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 17, 2025, 8:15 AM EDT - 7 months ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 12, 2025, 4:15 PM EDT - 7 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 6, 2025, 8:15 AM EST - 7 months ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Feb 21, 2025, 8:15 AM EST - 8 months ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 13, 2025, 8:15 AM EST - 8 months ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Jan 13, 2025, 8:15 AM EST - 9 months ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Dec 12, 2024, 8:15 AM EST - 10 months ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Nov 14, 2024, 4:36 PM EST - 11 months ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 8, 2024, 8:30 AM EST - 11 months ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 7, 2024, 8:30 AM EST - 11 months ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 6, 2024, 8:30 AM EST - 11 months ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:00 AM EST - 11 months ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 30, 2024, 5:00 PM EDT - 1 year ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Oct 29, 2024, 8:15 AM EDT - 1 year ago

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Oct 28, 2024, 8:15 AM EDT - 1 year ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Oct 21, 2024, 8:15 AM EDT - 1 year ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Oct 10, 2024, 8:15 AM EDT - 1 year ago

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Oct 9, 2024, 10:52 AM EDT - 1 year ago

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Oct 8, 2024, 8:15 AM EDT - 1 year ago

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Oct 3, 2024, 8:15 AM EDT - 1 year ago

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Sep 27, 2024, 8:15 AM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

ThomasJerryLLC Oct. 4 at 3:55 AM

$ADTX https://m.youtube.com/watch?v=2mkm_mNiJME&list=RD2mkm_mNiJME&start_radio=1&pp=ygUXdGhlcmUncyBubyBlYXN5IHdheSBvdXSgBwHSBwkJ-wkBhyohjO8%3D pardon Amro

0 · Reply

ijusshtmadrorss Oct. 3 at 3:16 PM

$ADTX short short short short.

0 · Reply

simonsteve Oct. 3 at 2:21 PM

$ADTX these idiots be doing split every year they hike the price up to make people buy at the top and they start draining the money gradually and split and repeat 🤬🤬🤬🤬

1 · Reply

VolticRaider2 Oct. 3 at 2:14 PM

$ADTX Let’s all shit on this stock cause we shorted it to .50! And now that it’s stable we are screwed! We gotta get it down!

0 · Reply

flyingcoyote Oct. 3 at 1:44 PM

$ADTX fraudulent company stealing American dollars.

0 · Reply

Ragnarok_74 Oct. 3 at 3:11 AM

$ADTX

0 · Reply

MoonCowBoy Oct. 3 at 1:40 AM

$FAMI $ADTX $NAOV $APDN (

0 · Reply

FrostyDaPoMan Oct. 2 at 11:24 PM

1 · Reply

1Spartantrade1 Oct. 2 at 6:59 PM

0 · Reply

exile0002 Oct. 2 at 5:28 PM

0 · Reply

JUNSimon Oct. 2 at 1:27 PM

$ADTX checking the highest in history n 52 weeks, you will understand how much shareholders' blood was dried by these crooks.

0 · Reply

jaetee66 Oct. 2 at 12:57 PM

$ADTX I fell for it at one point. You don't have to. Stay away.

1 · Reply

JUNSimon Oct. 2 at 12:31 PM

$ADTX fraudulent, fake news, dead weekly update …these crooks have been doing nothing but r/s to rob freely shareholders. SHAMELESS !!!

0 · Reply

exile0002 Oct. 2 at 10:35 AM

$ADTX 0,003008 pre RS !!!!!! Next RS in planning, continous dilution, this stock lost ~ 98% of its value in one year !!! That means the money behind is burned. Existing SH have NO chance to see their invested money again ... and for what? What did this management reached until now? This stock is dead on purpose, sorry such company management have to be indicted on fraud !!!

0 · Reply

BullsEyePick Oct. 2 at 4:59 AM

Looking for the next Monster runner?🚨🚨 Make sure you have ticker IVDA on ur watch. IVDA is Truly a gem of a ticker, known for big runs and perfect for a market like this where this can go on a massive rally of 400-500%+. IVDA has everything going for it, news/approved crypto treasury/Ai /Drone and most important of all it's a low float ticker. Be early bulls, because it will take off fast!!! $HCAI $REVB $ADTX $TEM

0 · Reply

MYBE Oct. 2 at 2:41 AM

$ADTX I really don't know when these criminals will have enough of stealing shareholders' money? Have the US Securities and Exchange Commission and the NASDAQ stock market management also lost their shame to allow such filth to occur in the market for three years while we support these idiots to no avail..! What is this? Aren't there fair and just leaders in this criminal market??? 😡😡😡

1 · Reply

MaxTradez Oct. 2 at 1:17 AM

$PAVS Holding this one until we see the $3 run. Massive consolidation and coiling $REBN added a little more today and still holding with my $AREB $CETX Tempted but scared from $ADTX history

0 · Reply

ricky_lafleur Oct. 1 at 10:37 PM

$ADTX scamro you can do better and drop it to 0.001$ 😂

0 · Reply

exile0002 Oct. 1 at 6:14 PM

$ADTX 81 % minus last 6 months .... and it continous ...... worst management ever !🤮🤮🤮

0 · Reply

Bossbaby14 Oct. 1 at 1:42 PM

$ADTX 3 mins and she's off

1 · Reply

JUNSimon Oct. 1 at 4:51 AM

$ADTX meeting robbery, honestly saying

0 · Reply

exile0002 Sep. 30 at 6:34 PM

$ADTX in which direction ?

0 · Reply

Market Cap	3.78M
Revenue (ttm)	130,000.00
Net Income (ttm)	-34.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26,500.00%
Debt to Equity Ratio	0.00

Volume	302,900
Avg Vol	304,654
Day's Range	N/A - N/A
Shares Out	4.98M
Stochastic %K	0%
Beta	1.48
Analysts	Strong Buy
Price Target	$61.00